{
    "organizations": [],
    "uuid": "f96df51b45ac095f334f7627ec30d729591950f6",
    "author": "",
    "url": "https://www.reuters.com/article/brief-celldexs-metric-study-in-metastati/brief-celldexs-metric-study-in-metastatic-triple-negative-breast-cancer-does-not-meet-primary-endpoint-idUSFWN1RT09Z",
    "ord_in_thread": 0,
    "title": "BRIEF-Celldex’S Metric Study In Metastatic Triple-Negative Breast Cancer Does Not Meet Primary Endpoint",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 16 (Reuters) - Celldex Therapeutics Inc:\n* CELLDEX’S METRIC STUDY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER DOES NOT MEET PRIMARY ENDPOINT\n* CELLDEX THERAPEUTICS INC - GLEMBATUMUMAB VEDOTIN SAFETY PROFILE WAS CONSISTENT WITH PRIOR EXPERIENCE\n* CELLDEX THERAPEUTICS INC - EVALUATING OUR OPERATIONAL AND WORKFORCE NEEDS TO EXTEND OUR FINANCIAL RESOURCES\n* CELLDEX THERAPEUTICS INC - RANDOMIZED, PHASE 2B METRIC STUDY OF GLEMBATUMUMAB VEDOTIN COMPARED TO XELODA FAILED TO MEET ITS PRIMARY ENDPOINT\n* CELLDEX THERAPEUTICS INC - NO SIGNIFICANT ADVANTAGE FOR GLEMBATUMUMAB VEDOTIN IN KEY SECONDARY ENDPOINTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-16T14:05:00.000+03:00",
    "crawled": "2018-04-16T14:20:50.030+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "celldex",
        "therapeutic",
        "inc",
        "celldex",
        "metric",
        "study",
        "metastatic",
        "breast",
        "cancer",
        "meet",
        "primary",
        "endpoint",
        "celldex",
        "therapeutic",
        "inc",
        "glembatumumab",
        "vedotin",
        "safety",
        "profile",
        "consistent",
        "prior",
        "experience",
        "celldex",
        "therapeutic",
        "inc",
        "evaluating",
        "operational",
        "workforce",
        "need",
        "extend",
        "financial",
        "resource",
        "celldex",
        "therapeutic",
        "inc",
        "randomized",
        "phase",
        "2b",
        "metric",
        "study",
        "glembatumumab",
        "vedotin",
        "compared",
        "xeloda",
        "failed",
        "meet",
        "primary",
        "endpoint",
        "celldex",
        "therapeutic",
        "inc",
        "significant",
        "advantage",
        "glembatumumab",
        "vedotin",
        "key",
        "secondary",
        "endpoint",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}